Results 111 to 120 of about 7,444 (141)

Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial. [PDF]

Aliment Pharmacol Ther
Inada H, Toyota T, Uojima H, Iio E, Miwa T, Miuma S, Miyase S, Mizuta T, Maeda D, Nagaoka K, Narahara S, Kurano S, Tanaka K, Yoshimaru Y, Watanabe T, Iwasaki S, Hidaka H, Sugi K, Setoyama H, Shimizu M, Nakayama J, Tanaka Y.   +21 more
europepmc   +1 more source

Intestinal decontamination with rifaximin attenuates LSEC dysfunction and liver fibrosis in mice. [PDF]

PLoS One
Su T, Lai S, Chen H.
europepmc   +1 more source

DYSBIOSIS IN ACUTE-ON-CHRONIC LIVER FAILURE - FROM A PATHOPHYSIOLOGICAL COMPONENT TO A THERAPEUTIC TARGET. [PDF]

Arq Gastroenterol
Mattos AA, Alves CA, Acuña J, Mattos AZ.   +3 more
europepmc   +1 more source

Letter to the Editor: Reassessing Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Comparative Study of Diagnostic Guidelines and Their Clinical Relevance. [PDF]

J Gastroenterol Hepatol
Zhuang H.
europepmc   +1 more source

Diarrhea management: from pathophysiology to microbiota modulation. [PDF]

Ther Adv Gastroenterol
Marasco G, Meacci D, Sarnelli G, Tosetti C, Cremon C, Savarino EV, Barbara G.   +6 more
europepmc   +1 more source

Clinical Challenges in the Management of Hepatic Encephalopathy in Older Patients with Cirrhosis: A Nationwide Italian Physician-Reported Survey. [PDF]

Medicina (Kaunas)
Lapenna L, Di Cola S, Nardelli S, Merli M.   +3 more
europepmc   +1 more source

Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth (SIBO). [PDF]

JGH Open
Shah A, Holtmann G, Gibson PR.
europepmc   +1 more source

A Novel Use of Tenapanor in Patients With Hepatic Encephalopathy: A Case Series. [PDF]

ACG Case Rep J
Yeo YH, Ayoub W, Rezaie A.
europepmc   +1 more source

Recurrent Hepatic Encephalopathy After Abdominal Surgery in a Non-Cirrhotic Patient: A Case Report. [PDF]

Reports (MDPI)
Ziola S, Cittadini G, Pasta A, Labanca S, Pieri G, Marenco S, Giannini EG.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Rifaximin

Hospital Pharmacy, 2010
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J. Cada, Terri L. Levien, Danial E. Baker   +2 more
  +4 more sources